Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 17, 2012
Event: Initiation of patent infringement litigation.
Key Financial Metrics
This filing is a current report regarding a legal event and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the commencement of legal action. On January 17, 2012, Alnylam filed a complaint in the U.S. District Court for the District of Massachusetts against Tekmira Pharmaceuticals Corporation ("Tekmira").
- Allegations: Tekmira is accused of patent infringement regarding research activities providing lipid nanoparticle (LNP)-formulated small interfering RNA (siRNA) molecules to a pharmaceutical collaborator.
- Patents Involved: U.S. Patent Nos. 7,695,902, 6,858,225, 6,815,432, 6,534,484, 6,586,410, and 6,858,224.
- Co-Plaintiff: Isis Pharmaceuticals, Inc. joined as a co-plaintiff regarding U.S. Patent No. 7,695,902, which Alnylam has the contractual right to enforce.
Outlook, Risks, and Contingencies
Relief Sought: Alnylam and Isis are seeking a judgment of infringement, a permanent injunction against Tekmira's activities, damages, and costs including attorneys' fees.
Risk Factor: The outcome of the litigation is uncertain. A loss could result in the invalidation of patents or an inability to enforce intellectual property rights, while a win could result in damages or injunctions against a competitor.
Investor Verification Checklist
- Verify the status of the lawsuit against Tekmira Pharmaceuticals Corporation.
- Confirm the validity and enforceability of the six cited U.S. patents.
- Assess the potential financial impact of legal costs versus potential damages or injunctions.
- Review the contractual agreement with Isis Pharmaceuticals regarding enforcement rights for Patent No. 7,695,902.